Pallas Health

What you're buying

Pallas sells one compounded GLP-1 plan per molecule and a cash-pay lane for the four brand drugs, and it wraps everything into a single figure: the clinician review, the medication if prescribed, dose adjustments, care-team messaging, an app and free shipping, with no separate membership fee. That last part is worth pausing on, because the two sellers Pallas is priced against both charge a membership on top.

Pallas is a technology platform operated by Brentmoor, Inc. It does not employ clinicians. Care is delivered by Lion MD, a nationwide clinical group, coordinated through a platform called CareValidate that verifies licensure and routes prescriptions. The site names one advising physician, Dr. Ana Lisa Carr, and links her NPI so you can check it in the federal registry. Alongside the weight-loss line there is an NAD+ program and sermorelin, with skincare and hormone therapy marked coming soon.

One thing to know before you compare this with anything else here. Lion MD — "our trusted partner … a nationwide team of US-licensed medical professionals", in the site's own words — is the same prescribing group that RxSpan MD and Sunlight name, and the physician Pallas puts at the head of it, Dr. Ana Lisa Carr, MD, carries the same NPI, 1689841744, that both of those sites publish. Pallas names no pharmacies today; the other two name overlapping lists. Shared clinical infrastructure is common in this market and there is nothing improper about it, but it does change what a comparison means. Choosing between these three is not choosing between three independent clinical opinions — much of what happens after you pay is the same operation behind a different storefront.

What it costs (and how it's billed)

Pallas advertises "$199/mo avg" and "$299/mo avg", and the word doing the work is average. There is no month-to-month rung for either compounded molecule. What Pallas actually sells, stated identically on the home page, the treatment page and the disclosure block in August 2026, is: compounded semaglutide at $139 for your first month, then $597 every 12 weeks; compounded tirzepatide at $179 for your first month, then $897 every 12 weeks. The advertised monthly average is that twelve-week charge divided by three.

Twelve weeks is 84 days, so the charge recurs about 4.35 times a year rather than four. On Pallas's own renewal terms that works out near $2,596 a year for semaglutide, about $216 a month, and near $3,900 a year for tirzepatide, about $325 a month — above the averages the marketing prints. The cash-flow shape is the likelier surprise: a small first payment, then four weeks later a single charge of $597, or $897 on tirzepatide.

The brand lane is billed monthly at pharmacy cash rates: Zepbound $1,069/mo, Ozempic $1,299/mo, Wegovy and Mounjaro $1,349/mo. Price is flat at every compounded dose — a step-up your clinician prescribes costs nothing extra — there is no minimum term, cancellation is self-serve from the portal, and a clinician who declines you refunds you in full.

Who can order

All fifty states plus Washington, D.C., and Pallas is unusually specific about how. In 43 states the visit is fully asynchronous, with no video call at all. Seven states — Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota and West Virginia — plus D.C. require one quick video visit. Publishing that split, by name, is better disclosure than most sellers manage.

Everything is private pay; Pallas never bills insurance, though HSA and FSA cards work and the site notes a letter of medical necessity may be required. Pay-over-time is offered at checkout.

How the intake works

The questionnaire runs about two minutes. A licensed clinician reviews it — often the same day — and prescribes if it is appropriate, and you are told the name and license information of your treating clinician before any prescription is issued. Medication ships free and discreetly from a US-licensed pharmacy, typically within a week. After that, refills, order tracking and provider messaging run through a portal at pallashealth.co/portal, with a companion app.

Support is a phone line, +1 (440) 601-3717, staffed Monday to Friday, 9 AM to 5 PM Eastern, plus hello@pallashealth.co and a mailing address in Newark, Delaware. No published response standard and no weekend cover.

What we'd want changed

Pallas used to name all six of the pharmacies that dispense for it and a second prescribing clinician. Neither is on the site now. The pharmacy list is gone entirely — the pages say only "US-licensed compounding pharmacies" — and the medical-team page names one physician where it once named two. That is a step backward on the exact disclosure Pallas was best at, and it is made worse by the state of the footer: on the day we read it, the links for Pricing, Common questions, How it works, State availability, Clinical disclosures, Provider directory and the FAQ all returned a 404 page.

Two smaller things. The footer states that some site content is AI-generated with no warranty as to accuracy, which is reason enough not to cite the blog for anything clinical, and the advertised 4.8 rating from 2,400-plus reviews carries no source you can check. And selling only a twelve-week charge while advertising a monthly average is a choice, not a constraint.

Bottom line

Pallas is honest about the number and coy about the shape. The four figures are the same everywhere on the site, nothing steps up at checkout, the dose-flat promise is real and the state rules are published in detail. But you are buying a quarterly prepay dressed as a subscription, and the real cost runs above the advertised average because twelve weeks is not three months. Take it if you can absorb $597 or $897 in one charge every twelve weeks and you value a fully asynchronous path in 43 states; skip it if you need to be able to stop after one month without having already paid for three.